Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Leuk Lymphoma. 2021 Apr;62(4):883-890. doi: 10.1080/10428194.2020.1855345. Epub 2020 Dec 4.
We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defined at least two suppressed uninvolved immunoglobulins. We found that patients with deep and partial immunoparesis had a significantly shorter median overall survival (OS) and progression-free survival (PFS). Moreover, deep and partial immunoparesis was a poor prognostic factor for OS and PFS in univariate and multivariable analyses. To reduce the bias between the groups, we performed a 1:1 propensity score matching technique for analysis and found that patients with deep and partial immunoparesis also had shorter OS and PFS. Our study showed that deep and partial immunoparesis can be defined an independent poor prognostic factor for patients with newly diagnosed MM.
我们回顾性分析了 287 例新诊断多发性骨髓瘤(MM)患者的免疫抑制状态,并评估了免疫缺陷对生存的预后价值。深度免疫缺陷定义为未受累免疫球蛋白之一低于正常范围下限的 50%,部分免疫缺陷定义为至少两种受抑制的未受累免疫球蛋白。我们发现,深度和部分免疫缺陷的患者中位总生存期(OS)和无进展生存期(PFS)明显缩短。此外,深度和部分免疫缺陷是单因素和多因素分析中 OS 和 PFS 的不良预后因素。为了减少组间偏倚,我们进行了 1:1 倾向评分匹配技术分析,发现深度和部分免疫缺陷的患者 OS 和 PFS 也较短。我们的研究表明,深度和部分免疫缺陷可作为新诊断 MM 患者的独立不良预后因素。